Published evidenceWhite paper
HYALOFAST®, a new biological approach for chondral and osteochondral lesion treatment
Author: Longinotti C.
Abstract (submitted to: ICRS 2013 Izmir, Turkey)
The field of conservative treatments for osteochondral and chondral lesions presents different approaches, many of which involve the contribution of cells directly at the lesion site. Specifically, autologous stem cells represent an attractive cell source due to their potential to differentiate both towards bone and cartilage and the possibility of representing a single step treatment.
Hyalofast®, a HYAFF11® based scaffold, is a support for autologous mesenchymal stem cells (MSCs) in the treatment of osteochondral and chondral lesions.
Preclinical in vitro and in vivo data have been collected to characterize Hyalofast® and demonstrate that, thanks to HYAFF11® biological properties and structural role, MSCs can properly regenerate chondral as well as osteochondral lesions, via successful differentiation towards the involved tissue lineages. Prospective clinical experience in the use of Hyalofast® for the one- step treatment of osteochondral lesions of the ankle and of the knee have been reported and confirmed the safety of the treatment and its short term good results in terms of clinical outcome and MRI assessed defect healing.
In conclusion, based on preclinical and clinical evidences, Hyalofast® appears a promising biological prostheses to be used in combination with autologous MSCs for the treatment of chondral and osteochondral lesions. Long term clinical data will be necessary to prove result durability.